Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.34 USD | -8.11% | -39.39% | -82.56% |
Mar. 28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
Mar. 28 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M | MT |
Financials (USD)
Sales 2023 | 19.59M | Sales 2024 * | 36.84M | Capitalization | 2.22M |
---|---|---|---|---|---|
Net income 2023 | -14M | Net income 2024 * | 5M | EV / Sales 2023 | 0.25 x |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 0.06 x |
P/E ratio 2023 |
-0.29
x | P/E ratio 2024 * |
0.44
x | Employees | 22 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 98.79% |
Latest transcript on Agile Therapeutics, Inc.
1 day | -8.11% | ||
1 week | -39.39% | ||
Current month | -57.23% | ||
1 month | -55.76% | ||
3 months | -82.29% | ||
6 months | -84.40% | ||
Current year | -82.56% |
Managers | Title | Age | Since |
---|---|---|---|
Al Altomari
CEO | Chief Executive Officer | 65 | 04-01-31 |
Scott Coiante
DFI | Director of Finance/CFO | 57 | 10-11-30 |
Paul Korner
CTO | Chief Tech/Sci/R&D Officer | 58 | 20-08-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Al Altomari
CEO | Chief Executive Officer | 65 | 04-01-31 |
Seth Fischer
BRD | Director/Board Member | 68 | 16-07-27 |
John Hubbard
BRD | Director/Board Member | 67 | 14-11-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.34 | -8.11% | 293,428 |
24-03-27 | 0.37 | +10.78% | 468,809 |
24-03-26 | 0.334 | -44.54% | 1,714,416 |
24-03-25 | 0.6022 | +10.11% | 2,983,826 |
24-03-22 | 0.5469 | -2.51% | 423,892 |
Delayed Quote OTC Markets, March 28, 2024 at 03:58 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-82.56% | 2.22M | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |